[ad_1]
Newcomer bio firms that went public on the KOSDAQ this yr are successively breaking by way of a market capitalization of 1 trillion received (roughly $680 million) in lower than a yr. That is the primary time that bio firms have entered the 1 trillion received market cap membership of their first yr of itemizing. Ok-Bio firms which have approached a market cap of 1 trillion received in lower than a yr since itemizing share the frequent attribute of getting confirmed tangible achievements akin to know-how exports to international pharmaceutical firms and improved efficiency. As Korea Change has raised the itemizing threshold, such separation of the wheat from the chaff is anticipated to proceed.
Based on the trade on Nov. 24, an evaluation of market cap tendencies of bio firms listed on KOSDAQ over the previous 5 years (2021-2025) revealed that Rokit Healthcare and Orum Therapeutics have surpassed 1 trillion received. That is the primary time that bio firms exceeding a market cap of 1 trillion received of their first yr of itemizing have emerged.
Rokit Healthcare, a man-made intelligence (AI) organ regeneration platform firm, went public on KOSDAQ by way of know-how particular itemizing in Might this yr. Contemplating that its market cap was solely 142.6 billion received on the primary day of itemizing with an providing worth of 11,000 received, this represents a surge of greater than seven occasions in six months. The corporate is at present promoting its world-first AI-based patient-customized pores and skin regeneration platform in 46 nations. Lately, ‘diabetic foot’ regenerative remedy was formally acknowledged as eligible for public insurance coverage protection at main tertiary hospitals (HOPD) in america, the place insurance coverage reimbursement charges are excessive. Enlargement of indications to pores and skin most cancers, cartilage, and kidney can also be a significant factor elevating company worth.
Orum Therapeutics went public in February this yr and exceeded a market cap of 1 trillion received early this month, 9 months after itemizing. As well as, Intocell and Protina, which additionally went public this yr, are approaching entry into the 1 trillion received membership.
A complete of seven bio firms joined the ‘market cap 1 trillion received membership’ within the KOSDAQ market this yr. In addition to Rokit Healthcare and Orum Therapeutics, D&D Pharmatech, CeARS Know-how, Ollix, GI Innovation, and Qurient have additionally surpassed the 1 trillion received market cap milestone. The attribute of this yr’s new members of the 1 trillion received membership is that the time to entry has been considerably shortened. The truth is, Voronoi, which at present exceeds a market cap of 4 trillion received, took two years to interrupt by way of 1 trillion received after its 2022 itemizing. Qurient surpassed 1 trillion received this month, about ten years after its 2016 itemizing.
The frequent attribute of bio firms that achieved the 1 trillion received membership this yr is that they’ve confirmed tangible achievements to the market, not simply development potential. They’ve gained recognition for his or her technological competitiveness by way of know-how exports or joint analysis with international pharmaceutical firms. Notably distinctive is that international pharmaceutical firms that licensed the know-how proceed to indicate improvement dedication, making the home bio firms’ pipelines their core belongings.
April Bio, a robust candidate for the 1 trillion received membership, has additionally gained recognition for its pipeline competitiveness from its know-how export companion. US-based Evommune is contemplating increasing the indication of the atopic dermatitis new drug candidate ‘EVO301(APB-R3)’ licensed from April Bio to ulcerative colitis. The trade interprets the revelation of the following indication earlier than even saying Part 2 medical outcomes as a show of confidence within the knowledge.
There may be additionally evaluation that development velocity is inevitably quick as solely verified firms go public attributable to not too long ago heightened itemizing thresholds. Han Sang-yeop, Vice President of LSK Funding, defined that “this displays the scenario the place wheat has been naturally separated from chaff as itemizing thresholds have been raised since a couple of years in the past.”
[ad_2]
